文献速递肝病

人工智能辅助数字病理用于非酒精性脂肪性肝炎:现状与未来方向

Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions.
PubMed 文献 · J Hepatol · 2023-10-24

非酒精性脂肪性肝炎(NASH)全球患病率上升且无获批治疗药物,药物研发依赖专家病理学家对肝活检的组织学分析,但存在样本异质性、阅片者间与阅片者内变异及序数评分系统等问题。本叙述性综述概述了用于NASH的数字病理(DP)与人工智能(AI)在研工具,强调关键监管考量,并讨论这些进展可能如何影响NASH临床管理与药物开发的未来。

要点

  • NASH药物研发需专家病理学家对肝活检进行组织学分析,但受样本异质性、阅片者间与阅片者内变异及序数评分系统限制。
  • DP/AI模型可自动检测、定位、定量和评分组织学参数,有望减少NASH临床试验中评分变异的影响。
  • DP/AI工具在NASH领域应成为高度优先事项,尤其为改善安全有效疗法的开发。

核心结论

  • DP/AI模型可自动检测、定位、定量和评分组织学参数,有望减少NASH临床试验中评分变异的影响。
  • DP/AI进展应成为NASH领域的高度优先事项,尤其为改善安全有效疗法的开发。

研究设计与样本

  • 叙述性综述,概述用于NASH的在研DP/AI工具,强调关键监管考量,并讨论其对NASH临床管理与药物开发未来的潜在影响。

主要发现

  • NASH全球患病率上升,造成显著医疗负担,但目前无获批治疗药物。
  • NASH药物研发需要专家病理学家对肝活检进行组织学分析以用于试验入组和疗效评估,但受样本异质性、阅片者间与阅片者内变异及序数评分系统等多重问题阻碍。
  • DP/AI模型可自动检测、定位、定量和评分组织学参数,并有可能减少NASH临床试验中评分变异的影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The worldwide prevalence of non-alcoholic steatohepatitis (NASH) is increasing, causing a significant medical burden, but no approved therapeutics are currently available. NASH drug development requires histological analysis of liver biopsies by expert pathologists for trial enrolment and efficacy assessment, which can be hindered by multiple issues including sample heterogeneity, inter-reader and intra-reader variability, and ordinal scoring systems. Consequently, there is a high unmet need for accurate, reproducible, quantitative, and automated methods to assist pathologists with histological analysis to improve the precision around treatment and efficacy assessment. Digital pathology (DP) workflows in combination with artificial intelligence (AI) have been established in other areas of medicine and are being actively investigated in NASH to assist pathologists in the evaluation and scoring of NASH histology. DP/AI models can be used to automatically detect, localise, quantify, and score histological parameters and have the potential to reduce the impact of scoring variability in NASH clinical trials. This narrative review provides an overview of DP/AI tools in development for NASH, highlights key regulatory considerations, and discusses how these advances may impact the future of NASH clinical management and drug development. This should be a high priority in the NASH field, particularly to improve the development of safe and effective therapeutics.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Ratziu V, Hompesch M, Petitjean M, et al. Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions. J Hepatol. 2023. PMID: 37879461. doi:10.1016/j.jhep.2023.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。